371 related articles for article (PubMed ID: 29569424)
1. Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity.
Bergamini C; Dolci G; Rossi A; Torelli F; Ghiselli L; Trevisani L; Vinco G; Truong S; La Russa F; Golia G; Molino A; Benfari G; Ribichini FL
Clin Cardiol; 2018 Mar; 41(3):349-353. PubMed ID: 29569424
[TBL] [Abstract][Full Text] [Related]
2. Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab.
Bergamini C; Niro L; Springhetti P; Ferri L; Trento L; Minnucci I; Maffeis C; Tafciu E; Rossi A; Fiorio E; Benfari G; Ribichini F
Cardiovasc Toxicol; 2024 Jun; 24(6):550-562. PubMed ID: 38696070
[TBL] [Abstract][Full Text] [Related]
3. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
4. Serial Measurements of Left Ventricular Systolic and Diastolic Function by Cardiac Magnetic Resonance Imaging in Patients with Early Stage Breast Cancer on Trastuzumab.
Song L; Brezden-Masley C; Ramanan V; Ghugre N; Barfett JJ; Chan KKW; Haq R; Petrella T; Dhir V; Jimenez-Juan L; Chacko BR; Kotha V; Connelly KA; Yan AT
Am J Cardiol; 2019 Apr; 123(7):1173-1179. PubMed ID: 30683420
[TBL] [Abstract][Full Text] [Related]
5. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
Honda K; Takeshita K; Murotani K; Mitsuma A; Hayashi H; Tsunoda N; Kikumori T; Murohara T; Ando Y
Breast Cancer; 2017 Mar; 24(2):312-318. PubMed ID: 27234030
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P
Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998
[TBL] [Abstract][Full Text] [Related]
8. Prolonged electromechanical delay as an early predictor of trastuzumab-induced cardiotoxicity in patients undergoing treatment for breast cancer.
Choe JC; Choi JH; Choi JH; Ahn J; Park JS; Lee HW; Oh JH; Lee HC; Cha KS; Hong TJ
Clin Cardiol; 2018 Oct; 41(10):1308-1314. PubMed ID: 30239009
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients.
Keramida K; Farmakis D; Bingcang J; Sulemane S; Sutherland S; Bingcang RA; Ramachandran K; Tzavara C; Charalampopoulos G; Filippiadis D; Kouris N; Nihoyannopoulos P
Eur J Heart Fail; 2019 Apr; 21(4):529-535. PubMed ID: 30811091
[TBL] [Abstract][Full Text] [Related]
10. Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data.
Kim EK; Cho J; Kim JY; Chang SA; Park SJ; Choi JO; Lee SC; Ahn JS; Park SW; Im YH; Jeon ES; Park YH
Cancer Res Treat; 2019 Apr; 51(2):727-736. PubMed ID: 30177584
[TBL] [Abstract][Full Text] [Related]
11. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
[TBL] [Abstract][Full Text] [Related]
12. Impacts of non-recovery of trastuzumab-induced cardiomyopathy on clinical outcomes in patients with breast cancer.
Yoon HJ; Kim KH; Kim HY; Park H; Cho JY; Hong YJ; Park HW; Kim JH; Ahn Y; Jeong MH; Cho JG; Park JC
Clin Res Cardiol; 2019 Aug; 108(8):892-900. PubMed ID: 30737527
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
[TBL] [Abstract][Full Text] [Related]
14. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of Left Atrial Remodeling in Predicting CardiacToxicity During Trastuzumab Therapy for Breast Cancer.
Bergamini C; Benfari G; Dolci G; Torelli F; Ghiselli L; Trevisani L; Truong S; Vinco G; La Russa F; Golia G; Molino A; Rossi A; Ribichini FL
Am J Cardiol; 2018 Sep; 122(5):885-889. PubMed ID: 30053998
[TBL] [Abstract][Full Text] [Related]
16. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
Hussain Y; Drill E; Dang CT; Liu JE; Steingart RM; Yu AF
Breast Cancer Res Treat; 2019 May; 175(1):239-246. PubMed ID: 30721443
[TBL] [Abstract][Full Text] [Related]
17. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction.
Nowsheen S; Aziz K; Park JY; Lerman A; Villarraga HR; Ruddy KJ; Herrmann J
J Am Heart Assoc; 2018 Aug; 7(15):e008637. PubMed ID: 30371238
[TBL] [Abstract][Full Text] [Related]
19. Deceleration capacity of heart rate predicts trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer: A prospective observational study.
Feng Y; Qin Z; Yang Z
J Clin Pharm Ther; 2021 Feb; 46(1):93-98. PubMed ID: 32975332
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy.
Calvillo-Argüelles O; Abdel-Qadir H; Michalowska M; Billia F; Suntheralingam S; Amir E; Thavendiranathan P
Can J Cardiol; 2019 Feb; 35(2):153-159. PubMed ID: 30760421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
